Hims Prescription and Intake Process: A Clinical Review

How the Hims Intake Process Actually Works

The Hims intake process is a digital-first, asynchronous medical questionnaire that feeds into a provider review. You complete a structured symptom and health-history form, answer condition-specific screening questions, and a licensed clinician reviews your responses before issuing or denying a prescription. For testosterone replacement therapy, Hims requires blood work before prescribing; for ED or hair loss, it generally does not.

Step 1: Online Questionnaire

The questionnaire covers chief complaint, relevant medical history, current medications, and allergy history. Depending on the condition, it takes eight to fifteen minutes. Questions for ED, for example, include cardiovascular risk screening because PDE-5 inhibitors like sildenafil are contraindicated with nitrate medications. The FDA's prescribing information for sildenafil explicitly lists nitrate co-administration as a contraindication due to severe hypotension risk. [1]

Hims screens for this via self-report. There is no pharmacist-to-pharmacy medication reconciliation at this stage, which means the safety net depends on the accuracy of patient disclosure.

Step 2: Clinician Review

A state-licensed nurse practitioner, physician assistant, or physician reviews the questionnaire asynchronously. Turnaround is typically same-day, sometimes within a few hours. For synchronous video visits (required in some states), the format mirrors a standard telehealth appointment.

The American Telemedicine Association's 2023 practice guidelines state that "an appropriate patient-provider relationship may be established via synchronous or asynchronous modalities provided the clinical scope is within the provider's licensure and the modality is appropriate to the complexity of the presenting condition." [2]

Hims's asynchronous model fits that standard for low-acuity conditions like ED or androgenetic alopecia. It is a less clear fit for testosterone replacement, where baseline and ongoing lab interpretation requires more clinical nuance.

Step 3: Prescription and Dispensing

Approved prescriptions route to Hims's affiliated pharmacy or, for compounded products, to a 503A or 503B compounding facility. The FDA distinguishes between 503A pharmacies (patient-specific compounding) and 503B outsourcing facilities (larger-scale, FDA-registered). [3] Hims has used both models for products like compounded topical finasteride-minoxidil combinations and compounded sildenafil troches.

What Hims Prescribes: Condition by Condition

Hims offers treatments across four primary clinical areas. The evidence base for each varies considerably.

Erectile Dysfunction

Hims prescribes sildenafil (generic Viagra) and tadalafil (generic Cialis). Both are FDA-approved PDE-5 inhibitors with strong trial evidence. A 2002 meta-analysis in the Annals of Internal Medicine covering 27 RCTs found sildenafil produced successful intercourse in 57% to 70% of men with ED versus 21% to 35% on placebo. [4]

Hims also offers compounded sildenafil troches (sublingual tablets). Compounded versions are not FDA-approved individually, but the active ingredient is the same approved molecule. The FDA has stated it does not typically take action against compounding of approved drugs when done by licensed pharmacies for legitimate medical purposes, provided certain conditions are met. [3]

Cost at Hims runs approximately $20 to $30 per month for generic sildenafil at lower doses.

Hair Loss

Finasteride 1 mg daily and topical minoxidil are the two primary offerings. Both are FDA-approved for androgenetic alopecia in men. [5] Finasteride's approval is based on two key trials showing 83% of men maintained or increased hair count at two years versus 28% on placebo. [6]

Hims also offers a proprietary topical finasteride plus minoxidil combination. A 2021 study published in JAMA Dermatology (N=458) found topical finasteride 0.25% plus minoxidil 3% produced superior hair count outcomes versus either agent alone at 24 weeks, with substantially lower serum DHT reduction than oral finasteride. [7] That reduced systemic absorption is clinically meaningful given finasteride's known risk of sexual side effects in a subset of men. [6]

Testosterone Replacement Therapy

Hims offers TRT via topical testosterone cream. This is a Schedule III controlled substance. For controlled substances, Hims requires labs before prescribing, specifically total testosterone, free testosterone, and a basic metabolic panel. This aligns with the American Urological Association's 2018 guideline stating that testosterone therapy should not be initiated without a confirmed low serum testosterone level on at least two morning measurements. [8]

The AUA guideline also recommends monitoring hematocrit, PSA, and testosterone levels at 3 and 6 months after initiation. [8] Hims does include follow-up lab requirements in its TRT protocol, though the frequency and breadth of monitoring depend on the prescribing clinician's discretion on the platform.

Hims does not prescribe injectable testosterone (e.g., testosterone cypionate), the most common and cost-effective TRT formulation in standard clinical practice. The restriction to topical cream limits options for men whose providers would typically recommend injections.

Mental Health

Hims prescribes SSRIs and SNRIs for depression and anxiety, primarily sertraline, escitalopram, and paroxetine. It also offers sertraline for premature ejaculation, an off-label use supported by a Cochrane review (N=2,614) that found SSRIs significantly prolonged intravaginal ejaculatory latency time. [9]

Mental health prescribing via asynchronous telehealth carries specific considerations. The 2023 American Psychiatric Association's telepsychiatry guidance recommends synchronous video as the preferred modality for initial psychiatric evaluations, given the importance of observational clinical data. [10] Hims uses asynchronous intake for SSRIs in many cases, which may miss clinical signals a video visit would capture.

Is Hims Legit? Regulatory and Safety Assessment

Hims, Inc. Is a publicly traded company (NYSE: HIMS) operating under state telehealth regulations and DEA licensing for controlled substances. Its prescribers hold active state licenses. Its affiliated pharmacies are licensed in their respective states. On those legal and regulatory metrics, Hims is a legitimate medical operation.

Provider Credentialing

Hims employs nurse practitioners and physician assistants as primary prescribers in most states. NPs and PAs are licensed independent practitioners authorized to prescribe controlled and non-controlled medications per their state scope-of-practice laws. The quality of the clinical review depends on individual clinician diligence, as with any telehealth or in-person practice.

Compounded Medication Risk

Compounded products from Hims carry the standard caveats of any compounded drug. They are not individually FDA-approved for efficacy or safety, they may have variable potency compared to FDA-approved finished products, and they are not subject to the same manufacturing standards as brand-name drugs. [3] A 2012 fungal meningitis outbreak linked to contaminated compounded steroids resulted in 64 deaths and prompted the Drug Quality and Security Act of 2013. [11] While Hims uses registered compounders, patients should be aware of these inherent differences.

Privacy and Data

Hims's privacy practices fall under HIPAA. The platform uses standard telehealth data security protocols. No major HIPAA enforcement actions against Hims have been publicly reported as of mid-2025.

Hims vs. Alternatives: A Comparative Framework

Choosing between Hims and competing telehealth platforms (or traditional in-person care) depends on condition complexity, preferred medication formulation, and budget. The table below organizes clinically relevant differentiators.

| Factor | Hims | Roman | Keeps | Traditional Urology/Endocrinology | |---|---|---|---|---| | ED prescribing | Yes, sildenafil/tadalafil + compounded | Yes | No | Yes, full formulary | | Hair loss | Yes, finasteride + minoxidil, topical combos | Yes | Yes, finasteride + minoxidil | Yes | | TRT (topical) | Yes, cream only | Yes | No | Yes, injections + topical | | TRT (injectable) | No | No | No | Yes | | Mental health | Yes, SSRIs/SNRIs | No | No | Psychiatry referral typical | | Intake modality | Async + sync | Async + sync | Async | In-person or sync telehealth | | Lab requirements (TRT) | Yes | Yes | N/A | Yes, plus imaging if indicated | | Compounded options | Yes | Limited | No | Rarely | | Monthly cost range | $20 to $150 | $22 to $165 | $25 to $50 | Variable, insurance-dependent |

For men whose primary concern is ED or androgenetic alopecia, Hims offers clinically appropriate medications at competitive prices with a low-friction intake. For men needing injectable TRT, more complex hormonal evaluation, or a comprehensive psychiatric assessment, in-person or synchronous specialist care is a better clinical fit.

Hims Men's HRT: What the Evidence Says

Testosterone replacement therapy for hypogonadism is an evidence-based treatment. The TRT Trials (N=790, average age 72) published in NEJM in 2016 found testosterone treatment significantly improved sexual function scores (IIEF domain, mean increase 2.64 points vs. 0.12 placebo, P<0.001) and modestly improved bone mineral density and anemia in older hypogonadal men. [12]

The AUA defines hypogonadism requiring TRT as total testosterone below 300 ng/dL confirmed on two separate morning measurements. [8] Hims's TRT protocol begins with lab confirmation, which is consistent with this standard.

Topical Testosterone: Absorption and Monitoring

Hims prescribes testosterone cream rather than gel (like AndroGel) or injections. Cream formulations have variable transdermal absorption depending on application site, skin hydration, and individual pharmacokinetics. A pharmacokinetic study in Journal of Clinical Endocrinology and Metabolism found testosterone cream achieved therapeutic levels in 75% to 80% of hypogonadal men, with greater day-to-day variability than injectable formulations. [13]

That variability means follow-up testosterone levels are essential to confirm therapeutic dosing. Hims's protocol includes follow-up labs at three months, which is appropriate per AUA guidance. [8]

Transfer Risk and Safety

Transdermal testosterone carries a documented risk of secondary transfer to female partners and children. The FDA issued a black-box warning for all topical testosterone products specifically citing this risk. [14] Hims's prescribing information and patient education materials address this, but patients should confirm they understand application-site covering and hand-washing protocols before initiating.

Hims Cost: What You Actually Pay

Hims uses a subscription model. One-time or month-to-month pricing is higher; three- or six-month prepaid plans reduce per-dose costs.

Sample Pricing (as of mid-2025)

• Generic sildenafil 20 mg (6 tablets): approximately $20/month
• Generic tadalafil 5 mg daily: approximately $30/month
• Finasteride 1 mg daily: approximately $25/month
• Topical finasteride/minoxidil combo: approximately $55 to $75/month
• Testosterone cream (TRT program, including labs): approximately $75 to $150/month
• Sertraline 50 mg daily: approximately $30/month

Hims does not accept insurance for most services. The consultation fee is typically bundled into the subscription. For men with insurance, GoodRx prices for generic sildenafil at retail pharmacies can be as low as $10 to $15 per month, making the telehealth convenience premium explicit.

Hidden Costs

Required lab work for TRT (if not covered by insurance) can add $100 to $200 per draw. Follow-up labs at three and six months bring total first-year TRT program costs to $1,200 to $2,200, depending on lab coverage. That is comparable to, or slightly above, typical out-of-pocket costs for TRT at a traditional men's health clinic.

Hims Reviews: Synthesizing Patient and Clinical Perspectives

Published patient satisfaction data on direct-to-consumer telehealth platforms is limited. A 2021 study in Journal of Medical Internet Research (N=2,411) found telehealth users reported high satisfaction with convenience (88%) but rated provider communication quality 12% lower than in-person visits. [15] That pattern is consistent with the asynchronous model: efficient, but with less back-and-forth.

For ED and hair loss specifically, the medications Hims prescribes are the same generic drugs available from any pharmacy. The value proposition is the consultation convenience, not a proprietary compound. For TRT, the platform's restriction to topical cream and its inability to prescribe injectable testosterone represent a real clinical limitation that some patients will outgrow and need to transition to traditional care.

The FDA's MedWatch database includes adverse event reports for sildenafil and finasteride consistent with their known side-effect profiles; there are no Hims-specific safety signals distinguishable from the broader class data in public records reviewed as of this writing. [16]